Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment

World Journal of Biological Psychiatry

Volumn 8, Issue 1, 2007, Pages 42-44

  Ozen, Murat Eren ^a   Yumru, Mehmet ^a   Savas, Haluk ^a   Cansel, Neslihan ^a   Herken, Hasan ^b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b PAMUKKALE UNIVERSITY   (Turkey)

Author keywords

Neuroleptic malignant syndrome; Schizophrenia; Treatment; Ziprasidone

Indexed keywords

BIPERIDEN; DIAZEPAM; OLANZAPINE; ZIPRASIDONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE DURATION; DRUG URINE LEVEL; HUMAN; MALE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; RECTUM TEMPERATURE; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPERIDEN; DIAGNOSIS, DIFFERENTIAL; DIAZEPAM; DRUG THERAPY, COMBINATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; PARKINSONIAN DISORDERS; PIPERAZINES; SCHIZOPHRENIA; THIAZOLES;

EID: 33847168475     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970600774202     Document Type: Article

References (16)

1. (2000) Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association
2. Anne, WS, Lorraine, AL, Howard Jr, HR and Stevin, HZ (2001) Ziprasidone: A novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol, 425, pp. 197-201.
3. Bora, E., Gönül, AS, Akdeniz, F. and Vahip, S. (2003) Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. Eur Psychiatry, 18, pp. 322-323.
4. Colloberative Working Group (1998) Adverse effects of the atypical antipsychotics. J Clin Psychiatry, 12, pp. 17-22.
5. Chouinard, G., Ross-Chouinard, A., Annable, L. and Jones, BD (1980) Extrapyramidal symptom rating scale. Can J Neurol Sci, 7, p. 233.
6. Elechi, CA (1992) Neuroleptic malignant syndrome complicating tetanus treated with chlorpromazine. Trop Doct, 22, pp. 92-93.
7. Gray, NS (2004) Ziprasidone-related neuroleptic malignant syndrome in a patient with Parkinson's disease: A diagnostic challenge. Hum Psychopharmacol, 19, pp. 205-207.
8. Hasan, S. and Buckley, P. (1998) Novel antipsychotics and the neuroleptic malignant syndrome: A review and critique. Am J Psychiatry, 155, pp. 1113-1116.
9. Leibold, J., Patel, V. and Hasan, RA (2004) Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther, 26, pp. 1105-1108.
10. Lew, TY and Tollefson, G. (1983) Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam. Biol Psychiatry, 18, pp. 1441-1446.
11. Mahmood, T. and Warren, JP (1989) Neuroleptic malignant syndrome from chlorpromazine: Case report. J R Coll Gen Pract, 39, p. 211.
12. Rasmussen, KG (1998) Risk Factors for neuroleptic malignant syndrome. Am J Psychiatry, 155, pp. 1639-1640.
13. (2000) Kaplan and Sadock's Comprehensive Textbook of Psychiatry, p. 2266. Lippincott, Williams and Wilkins
14. Sadock, BJ and Sadock, VA (2003) Kaplan and Sadock's synopsis of psychiatry: Behavioral sciences - clinical psychiatry, p. 998. Lippincott, Williams and Wilkins
15. Shad, P. (1998) Pharmacodynamic and pharmacokinetic factors in a cese of neuroleptic malignant syndrome. J Clin Psychopharmacol, 18, pp. 346-347.
16. Sing, KJ, Ramaekers, GM and Van Harten, PN (2002) Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry, 159, pp. 149-150.